Related Experiment Video

Updated: Aug 19, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Toxic myopathies

Ronan J Walsh1, Anthony A Amato

  • 1Neuromuscular Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA. rjwalsh@partners.org

Neurologic Clinics
|March 11, 2005
PubMed

Insights

Early recognition of toxic myopathies is crucial for potential recovery. Promptly removing the causative drug or toxin improves the chances of full muscle function restoration.

Area of Science:

  • Pharmacology
  • Toxicology
  • Neurology

Background:

  • Muscle tissue's high metabolic activity makes it susceptible to drug and toxin-induced damage.
  • Toxic myopathies can manifest with a spectrum of symptoms, from mild pain to severe muscle breakdown (rhabdomyolysis) and organ failure.
  • Understanding the multifactorial pathogenic bases is key to managing these conditions.

Purpose of the Study:

  • To review drugs commonly causing toxic myopathies.
  • To detail the clinical and histopathologic features of drug-induced myopathies.
  • To illustrate potential cellular mechanisms underlying toxic myopathies.

Main Methods:

  • Literature review of drugs associated with toxic myopathy.
  • Analysis of clinical presentations and histopathologic findings.
  • Exploration of cellular pathways affected by myotoxic agents.

Main Results:

  • Identified key drugs implicated in toxic myopathies.
  • Described characteristic clinical and histopathologic manifestations.
  • Provided insights into the cellular mechanisms of muscle injury.

Conclusions:

  • Early identification and removal of offending agents are vital for favorable outcomes in toxic myopathies.
  • Diverse drugs can induce myotoxicity through various cellular disruptions.
  • Further research into cellular mechanisms can guide therapeutic strategies.

More Related Videos

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

Immunolabelling Myofiber Degeneration in Muscle Biopsies06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...